BioRestorative exchanges preferred shares with Auctus, replaces auditor after Friedman/Marcum merger

BioRestorative Therapies, Inc.

Issued 1,543,158 Series B preferred shares to Auctus Fund in exchange for same number of Series A shares on Sept 8, 2022.
Series B preferred stock raises beneficial ownership limitation to 9.99% of common stock (up from 4.99% for Series A).
Audit Committee dismissed Friedman LLP and engaged Marcum LLP as independent auditor on Sept 13, 2022, following Friedman's combination with Marcum.
Friedman's reports for FY2020 and FY2021 were unqualified with no disagreements or reportable events.

item 1.01 item 4.01 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.